Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
It is the first monoclonal antibody drug for use in any animal species
Subscribe To Our Newsletter & Stay Updated
